Exonhit Therapeutics, SA
USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Exonhit ranks #46,631 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.
- #46,631
- of 49,997 US assignees by volume
- 5th percentile
- by Innovation Score (18.5/100)
- 8.8
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R46631 · Foreign Corporation #46,631 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 5 grants
- BOTTOM-DECILE #46,631/49,997
- PHOTO-FINISH Exelway
- CPC-NARROW C07D · 4 areas
- INNOV-LOW 18.5/100
- CLAIMS-PAR 8.8 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Exelway Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Exonhit’s 18.5 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Exonhit
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Exonhit Therapeutics · this assignee 19
Exonhit Therapeutics · this assignee
19 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Exonhit's Innovation Score is 18.5/100 (5th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Exonhit?
Each dot is one of Exonhit’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Exonhit’s own 8.8 claims/patent is at or below the 15.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Exonhit's grants concentrate
Exonhit Therapeutics, SA is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2015. By volume, Exonhit sits between Exelway Inc. and Expanded Existence, Inc..
Who files at Exonhit's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Exelway
Exelway Inc.
5 patents
- Exhalation Techno…
Exhalation Technology Limited
5 patents
- Exhaustless
Exhaustless, Inc.
5 patents
- Exoiq
Exoiq GMBH
5 patents
- Exostemtech
Exostemtech Co., Ltd.
5 patents
- Exotec Solutions
Exotec Solutions
5 patents
- Exotex
Exotex, Inc.
5 patents
- Expanded Existence
Expanded Existence, Inc.
5 patents
- Exonhit Therapeut… ◀
Exonhit Therapeutics, SA
5 patents
What this shows Exonhit holds 5 patents at rank #46,491, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Exonhit
By rank, the assignees closest to #46,491 in granted patent volume.
- Exelway Inc. #46,487 · 5 patents
- Exhalation Technology Limited #46,488 · 5 patents
- Exhaustless, Inc. #46,489 · 5 patents
- Exoiq GMBH #46,490 · 5 patents
- Exostemtech Co., Ltd. #46,492 · 5 patents
- Exotec Solutions #46,493 · 5 patents
- Exotex, Inc. #46,494 · 5 patents
- Expanded Existence, Inc. #46,495 · 5 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Exonhit's primary technology class.
Exonhit's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
19 5th percentile higher than 5% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 20.0% |
| 2016 | 1 | 20.0% |
| 2017 | 2 | 40.0% |
| 2018 | 1 | 20.0% |
Which technologies does Exonhit Therapeutics, SA patent most?
Top 4 of 4 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Exonhit Therapeutics, SA's patent record in context - here's where to go next.
- Exonhit Therapeutics, SA's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #46,631 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Exonhit Therapeutics, SA against Exelway Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 18.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.